Network Version
Scriptaid Data Sheet
| Product Name: | Scriptaid |
 |
|---|---|---|
| CAS No.: | 287383-59-9 | |
| Cat. No.: | HY-15489 | |
| MWt: | 326.35 | |
| Formula: | C18H18N2O4 | |
| Purity : | >98% | |
| Solubility: | DMSO : 100 mg/mL (306.42 mM; Need ultrasonic) | |
| Mechanisms: | Target: Cancer | |
| Biological Activity: | ||
| Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment. IC50 & Target: HDAC[1] In Vitro: Scriptaid (1 µg/mL) treatment inhibits cell growth in breast cancer cell lines, results in increased accumulation of both acetyl H3 and acetyl H4 proteins in MDA-MB-231, MDA-MB-435, and Hs578t cells. Scriptaid also inhibits cell growth of MDA-MB-231, MDA-MB-435, and Hs578t cell lines, with IC50s of 0.5-1.0 µg/mL. Scriptaid (0.1-1.0 µg/mL) induces ER and PR mRNA expression in a dose dependent manner; when it is combined with AZA, they enhance ER expression and induce a functional ER protein[1]. Scriptaid and SAHA preferentially inhibit the Class I histone deacetylases, hdac1, 2, and 3. Scriptaid is a potent anti-T. gondii compound with low cytotoxicity, and the IC50 is 39 nM. Scriptaid has atypical effects in T. gondiiinfected HS68 cells[2]. Scriptaid inhibits the growth of HeLa cells with IC50 of 2 μM at 48 h in a dose-dependent manner. Scriptaid also affects cell-cycle and apoptosis[3]. In Vivo: Scriptaid (3.5 µg/g mouse, i.p.) clearly inhibits tumor growth in a xenograft mouse model[1]. | ||
1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com